Bank of America’s UroGen Pharma URGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.28M Sell
126,783
-1,847
-1% -$37K ﹤0.01% 4032
2025
Q4
$3.01M Buy
128,630
+20,176
+19% +$438K ﹤0.01% 3754
2025
Q3
$2.16M Sell
108,454
-156,663
-59% -$2.81M ﹤0.01% 4763
2025
Q2
$3.63M Buy
265,117
+68,315
+35% +$656K ﹤0.01% 4212
2025
Q1
$2.18M Buy
196,802
+124,330
+172% +$1.33M ﹤0.01% 4606
2024
Q4
$772K Buy
72,472
+5,983
+9% +$71.6K ﹤0.01% 5241
2024
Q3
$844K Buy
66,489
+403
+0.6% +$5.98K ﹤0.01% 5167
2024
Q2
$1.11M Buy
66,086
+13,023
+25% +$185K ﹤0.01% 4846
2024
Q1
$796K Sell
53,063
-18,601
-26% -$304K ﹤0.01% 5076
2023
Q4
$1.07M Buy
71,664
+28,326
+65% +$368K ﹤0.01% 4931
2023
Q3
$607K Buy
43,338
+11,759
+37% +$189K ﹤0.01% 5188
2023
Q2
$327K Sell
31,579
-99,036
-76% -$1.09M ﹤0.01% 5535
2023
Q1
$1.21M Buy
130,615
+10,139
+8% +$93.3K ﹤0.01% 4780
2022
Q4
$1.07M Buy
120,476
+404
+0.3% +$3.83K ﹤0.01% 4803
2022
Q3
$999K Sell
120,072
-3,535
-3% -$29.2K ﹤0.01% 4881
2022
Q2
$1.01M Sell
123,607
-4,710
-4% -$32.3K ﹤0.01% 4893
2022
Q1
$1.12M Buy
128,317
+87,055
+211% +$679K ﹤0.01% 5126
2021
Q4
$392K Buy
41,262
+4,719
+13% +$66.5K ﹤0.01% 6062
2021
Q3
$614K Sell
36,543
-53,092
-59% -$842K ﹤0.01% 5484
2021
Q2
$1.37M Buy
89,635
+56,313
+169% +$1.02M ﹤0.01% 4637
2021
Q1
$650K Sell
33,322
-864
-3% -$18.3K ﹤0.01% 5171
2020
Q4
$616K Buy
34,186
+21,227
+164% +$445K ﹤0.01% 4859
2020
Q3
$250K Sell
12,959
-706
-5% -$16K ﹤0.01% 5164
2020
Q2
$357K Buy
13,665
+895
+7% +$21.9K ﹤0.01% 4863
2020
Q1
$228K Buy
12,770
+3,871
+43% +$105K ﹤0.01% 5009
2019
Q4
$297K Sell
8,899
-500
-5% -$13.6K ﹤0.01% 5369
2019
Q3
$223K Buy
9,399
+2,695
+40% +$88.1K ﹤0.01% 5606
2019
Q2
$241K Sell
6,704
-12,720
-65% -$469K ﹤0.01% 5531
2019
Q1
$717K Buy
19,424
+17,553
+938% +$736K ﹤0.01% 4770
2018
Q4
$81K Buy
1,871
+814
+77% +$36.6K ﹤0.01% 6020
2018
Q3
$50K Hold
1,057
﹤0.01% 6215
2018
Q2
$53K Buy
+1,057
New +$61.5K ﹤0.01% 6112

Other funds holding URGN